Jpmorgan Chase & CO Cyclo Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 194 shares of CYTH stock, worth $116. This represents 0.0% of its overall portfolio holdings.
Number of Shares
194
Previous 153
26.8%
Holding current value
$116
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CYTH
# of Institutions
20Shares Held
2.25MCall Options Held
0Put Options Held
0-
Epiq Capital Group, LLC San Francisco, CA739KShares$443,6550.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA599KShares$359,2160.0% of portfolio
-
Founders Fund V Management, LLC San Francisco, CA481KShares$288,4247.36% of portfolio
-
Geode Capital Management, LLC Boston, MA152KShares$91,3990.0% of portfolio
-
Founders Fund Vi Management, LLC San Francisco, CA110KShares$66,01318.16% of portfolio
About Cyclo Therapeutics, Inc.
- Ticker CYTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 8,439,440
- Market Cap $5.06M
- Description
- Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...